Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

Editas Medicine Inc (EDIT) USD0.0001

Sell:$49.50 Buy:$49.71 Change: $0.56 (1.14%)
NASDAQ:0.99%
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Sell:$49.50
Buy:$49.71
Change: $0.56 (1.14%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Sell:$49.50
Buy:$49.71
Change: $0.56 (1.14%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Contact details

Address:
11 Hurley St
CAMBRIDGE
02141-2110
United States
Telephone:
+1 (617) 4019000
Website:
www.editasmedicine.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EDIT
ISIN:
US28106W1036
Market cap:
$3.25 billion
Shares in issue:
66.19 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Mullen
    President, Chief Executive Officer, Director
  • Michelle Robertson
    Chief Financial Officer
  • Lisa Michaels
    Executive Vice President, Chief Medical Officer
  • Harry Gill
    Senior Vice President - Operations
  • Gad Berdugo
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.